Pharming Group (NASDAQ:PHAR – Get Free Report) and Immix Biopharma (NASDAQ:IMMX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Profitability
This table compares Pharming Group and Immix Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pharming Group | -2.19% | -3.31% | -1.78% |
| Immix Biopharma | N/A | -205.35% | -110.63% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Pharming Group and Immix Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pharming Group | 0 | 1 | 3 | 0 | 2.75 |
| Immix Biopharma | 0 | 1 | 1 | 0 | 2.50 |
Insider and Institutional Ownership
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 55.4% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Pharming Group has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.
Earnings and Valuation
This table compares Pharming Group and Immix Biopharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pharming Group | $339.84 million | 3.02 | -$11.84 million | ($0.13) | -115.34 |
| Immix Biopharma | N/A | N/A | -$21.61 million | ($0.77) | -2.73 |
Pharming Group has higher revenue and earnings than Immix Biopharma. Pharming Group is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Pharming Group beats Immix Biopharma on 7 of the 13 factors compared between the two stocks.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
About Immix Biopharma
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
